Inge S. van Houdt

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression

Inge S. van Houdt, Berbel J.R. Sluijter, Laura M Moesbergen et al. · International Journal of Cancer · 2008 · 136 citations · Full text

Mhc Class, Immunology, Pathology +19

Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients with Stage III and IV Melanoma

Inge S. van Houdt, Joost J. Oudejans, Alfonsus Johannes Maria van den Eertwegh et al. · Clinical Cancer Research · 2005 · 90 citations · Full text

Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas

Jettie J.F. Muris, Saskia A.G.M. Cillessen, Wim Vos et al. · Blood · 2004 · 84 citations · Full text

Tetraspanin CD37 protects against the development of B cell lymphoma

Charlotte M. de Winde, Sharon Veenbergen, Ken H. Young et al. · Journal of Clinical Investigation · 2016 · 59 citations · Full text

Lymphoid Neoplasia, Lymphocyte Development, Lymphoma Development +14

Intracellular serpin SERPINB6 (PI6) is abundantly expressed by human mast cells and forms complexes with β-tryptase monomers

Merel C. M. Strik, Angela M. Wolbink, Dorine Wouters et al. · Blood · 2003 · 40 citations